Korets, Sharmilee Bansal <br/><br/>
Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.  [electronic resource] 

 -  Gynecologic oncology  Feb 2014 
 - 468-73 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2013.11.027  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Carboplatin--administration & dosage<br/>Carcinoma, Endometrioid--drug therapy<br/>Cell Growth Processes--drug effects<br/>Cell Line, Tumor<br/>Endometrial Neoplasms--drug therapy<br/>Everolimus<br/>Female<br/>Indoles--pharmacology<br/>Mechanistic Target of Rapamycin Complex 1<br/>Mechanistic Target of Rapamycin Complex 2<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Multiprotein Complexes--antagonists & inhibitors<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins c-akt--antagonists & inhibitors<br/>Purines--pharmacology<br/>Random Allocation<br/>Signal Transduction<br/>Sirolimus--administration & dosage<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays